Specific bacterial subspecies, often resistant to traditional antibiotics, are the cause of severe problems like Hospital-Acquired Infections and sepsis. Reducing both time and costs for identification of these subspecies, thus diagnosing more efficiently infectious diseases, is crucial for our health systems. Current solutions in the field are based on expensive and time-consuming methods, and the fast, cost-efficient existing technologies, like MALDI-TOF MS, are restricted to the identification of main bacterial species, but are unable to go down to the subspecies level. Clover Biosoft is leveraging the power of modern AI techniques to develop algorithms using MALDI-TOF MS data to successfully classify bacterial subspecies. Ours is a collaborative project assisted by several first-level public hospitals and cutting-edge scientists from various European universities. Time-to-market is essential, and the market is ripe for our solution. MALDI-TOF MS instruments have become a standard in microbiology laboratories worldwide, allowing a very easy integration with our software. Moreover, the increasing number of patients affected by HAIs and the growing resistance to antibiotics, have raised the public concern, becoming a priority now for public and private health system managers and governments. Clover Biosoft is the ideal player to take this solution to the market, because of our long experience in the field and our extensive network, including all relevant type of stakeholders, from hospitals to big vendor companies and from researchers to government officials. Our team has the perfect combination of technical prowess, scientific background and business acumen. Our company has obtained solid revenues from its inception. Combining public and private investment, we are confident to take this project to market and become a reference for clinical diagnosis software development, bringing wealth and work to our region.

MALDIBANK: A Comprehensive Solution to Microbial Challenges In an era marked by pressing environmental and health challenges, including climate change, biodiversity loss, global epidemics, and food security, understanding and leveraging the power of microbes is critical. Microbes, fundamental to the biosphere, impact everything from ecosystem dynamics to human health. However, their vast diversity remains largely underestimated. To harness this potential, precise identification of microorganisms is crucial, especially given their varied implications across different sectors. Over the past 15 years, MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight) mass spectrometry (MS) has revolutionized microbial identification in fields such as clinical microbiology, food safety, environmental monitoring, and sustainable agriculture. Despite its transformative potential, MALDI-TOF MS technology has been underutilized outside clinical microbiology. MALDIBANK emerges as a groundbreaking initiative to extend the reach of this technology, providing innovative solutions for understanding and utilizing microbial diversity for global problem-solving. MALDIBANK is conceptualized as a global, cloud-based, open MALDI spectra databank for the identification of microorganisms, combining a vast spectrum database with advanced algorithmic tools. This databank will facilitate processing, characterization, epidemiological surveillance, and more, embodying Open Science and FAIR data principles. It aims to become a new reference in microbial identification, drawing parallels with the impact of GenBank in genomics. By integrating 100,000 reference spectra with rich metadata and employing deep learning models, MALDIBANK will enhance microbial characterization and support areas like antimicrobial resistance prediction and environmental monitoring. It will serve as a dynamic resource for the global scientific community, enabling the exploration of microbial capabilities an